Amphastar Pharma (AMPH) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018
May 9, 2018 4:05 PM EDTReports Net Revenues of $58.4 Million for the Three Months Ended March 31, 2018
RANCHO CUCAMONGA, Calif., May 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (Amphastar or the Company) today reported results for the three months ended March 31, 2018.
First Quarter Highlights
Net revenues of $58.4 million for the first quarterGAAP net loss of $7.2 million, or $0.16 per share, for the first quarterAdjusted non-GAAP net loss of $2.5 million, or $0.05 per share, for the first quarterDr. Jack Zhang, Amphastars CEO, commented:Â We are pleased to announce that we have... More
